Table 1. Demographics and characteristics of case and control groups.
| Characteristic | Case(n = 1016) | Control (n = 4064) | P value |
|---|---|---|---|
| Age( years) | 65.5 ± 18.6 | 63.9 ± 17.9 | 0.08 |
| Female(%) | 42.1% | 40.9% | 0.23 |
| Male(%) | 57.9% | 59.1% | 0.25 |
| Smoking history(Y) (%) | 70.7% | 68.8% | 0.07 |
| Smoking history(N) (%) | 29.3% | 31.2% | 0.10 |
| SCLC(%) | 12.5% | 14.2% | 0.18 |
| NSCLC(%) | 87.5% | 85.8% | 0.15 |
| Adenocarcinoma(%) | 46.7% | 43.6% | 0.33 |
| Squamous(%) | 28.1% | 29.5% | 0.19 |
| Large cell(%) | 8.6% | 9.3% | 0.24 |
| Stage I(%) | 18.7% | 20.2% | 0.26 |
| Stage II(%) | 21.6% | 22.8% | 0.22 |
| Stage III(%) | 28.4% | 27.9% | 0.17 |
| Stage IV(%) | 31.3% | 29.1% | 0.16 |
| Chemotherapy(%) | 76.7% | 73.1% | 0.38 |
| Cancer surgery(%) | 45.5% | 42.9% | 0.27 |
| Anticoagulation(LCR) (%) | 32.1% | 34.2% | 0.16 |
| Coagulation(LCR)(%) | 10.8% | 11.1% | 0.22 |
| Progression(%) | 78.8% | 31.4% | < 0.001 |
| Recurrence(%) | 31.9% | 18.2% | 0.02 |
| DVT(%) | 44.9% | 20.3% | 0.003 |
| D-Dimer(mg/L) | 2.67 ± 1.35 | 0.62 ± 0.33 | < 0.001 |
Note: (%): the proportion in case or control group; SCLC: small cell lung cancer; NSCLC: non small cell lung cancer; Stage: TNM stage; LCR: lung cancer-related; DVT: deep venous thromboembolism